{"brief_title": "A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.", "brief_summary": "The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer", "condition": ["Colorectal Cancer"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["ALIMTA", "Oxaliplatin"], "criteria": "Inclusion Criteria: - Diagnosis of primary cancer of the colon or rectum - Must have measurable disease - Must be able to comply with study procedure Exclusion Criteria: - Prior chemotherapy for advanced disease - Pregnancy or lactation - Candidates for surgical resection of one or more metastatic foci - Second primary cancer - Inability to take folic acid or vitamin B12", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Colorectal Neoplasms", "Oxaliplatin", "Pemetrexed"], "id": "NCT00034619"}